甘露醇输注降低68Ga-PSMA肾脏摄取:初步结果
本研究在9例接受68Ga-PSMA PET/CT的患者中,比较基线及静脉输注500 ml 10%甘露醇后肾脏SUVmax的变化,采用两种输注方案:A方案为68Ga-PSMA给药后40分钟内输注500 ml甘露醇,B方案为给药前15分钟内输注250 ml并在给药后再次输注250 ml。结果A方案右肾和左肾平均SUVmax分别增加11.9%和7.4%,B方案分别降低24.3%和22.4%。作者初步认为甘露醇可能有助于降低68Ga-PSMA的肾脏脱靶摄取,且快速给药并早于68Ga-PSMA注射开始可能更有效,结果需在177Lu-PSMA治疗患者中开展剂量学研究以确定最佳甘露醇给药方案。
要点
- A方案(给药后40分钟内输注500 ml甘露醇)右肾和左肾平均SUVmax分别增加11.9%和7.4%。
- B方案(给药前15分钟内输注250 ml并在给药后再次输注250 ml)右肾和左肾平均SUVmax分别降低24.3%和22.4%。
- 作者初步认为甘露醇可能有助于降低68Ga-PSMA肾脏脱靶摄取,需在177Lu-PSMA治疗患者中开展剂量学研究。
核心结论
- 作者初步认为甘露醇可能有助于降低68Ga-PSMA的肾脏脱靶摄取。
- 作者认为渗透性利尿剂应快速给药并早于68Ga-PSMA注射开始。
- 这些结果需在177Lu-PSMA治疗患者中开展剂量学研究,以确定最佳甘露醇给药方案。
研究设计与样本
- 在9例接受68Ga-PSMA PET/CT的患者中计算基线(b-PET/CT)和静脉输注500 ml 10%甘露醇后(m-PET/CT)的肾脏SUVmax。
- 采用两种甘露醇输注方案:A方案为68Ga-PSMA给药后40分钟内输注500 ml甘露醇;B方案为68Ga-PSMA给药前15分钟内输注250 ml并在给药后再次输注250 ml。
主要发现
- 接受A方案的患者右肾和左肾平均SUVmax分别增加11.9%和7.4%。
- 接受B方案的患者右肾和左肾平均SUVmax分别降低24.3%和22.4%。
局限性
- 原文为初步结果(preliminary findings)。
- 这些结果需在177Lu-PSMA治疗患者中开展剂量学研究,以确定最佳甘露醇给药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Urea-based prostate-specific membrane antigen (PSMA) ligands labelled with 68Ga or 177Lu are new tracers with great potential for theranostic approaches in prostate cancer. However, clinical studies have shown that the kidneys are one of the off-target organs along with the salivary and lacrimal glands. In the kidneys, PSMA is physiologically expressed in the apical epithelium of the proximal tubules, and mannitol acts as an osmotic diuretic in these tubules. We investigated the potential of mannitol to reduce renal uptake of 68Ga-PSMA. METHODS: Kidney uptake (SUVmax) was calculated in nine patients undergoing 68Ga-PSMA PET/CT at baseline (b-PET/CT) and after intravenous infusion of 500 ml of 10% mannitol (m-PET/CT). Two different infusion schemes for mannitol were used: (1) 500 ml mannitol was infused over 40 min after 68Ga-PSMA administration (A-infusion) and (2) 250 ml mannitol was infused over 15 min before and again after 68Ga-PSMA administration (B-infusion). RESULTS: In patients receiving the A-infusion, mean SUVmax increased by 11.9% and 7.4% in the right and left kidney, respectively. In patients receiving the B-infusion, mean SUVmax decreased by 24.3% and 22.4% in the right and left kidney, respectively. CONCLUSION: Our preliminary findings indicate that mannitol may play a role in reducing off-target 68Ga-PSMA renal uptake. Administration of the osmotic diuretic should be rapid and start before 68Ga-PSMA injection. These results warrant dosimetric studies in patients treated with 177Lu-PSMA to find the best scheme for mannitol administration.
引用
- Matteucci F, Mezzenga E, Caroli P, et al. Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results. Eur J Nucl Med Mol Imaging. 2017. PMID: 28801787. doi:10.1007/s00259-017-3791-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。